Español | English
Find
Contact | Legal Notice | Web Map | Recommend
Home > Pressroom > Press Releases

Press Releases

Year

1 2 Next
15/07/2010
Noscira presents results of Phase IIa clinical trial with Nypta® (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)  More Information

- Treatment with Nypta® (Tideglusib) (NP-12) was tolerated and produced positive effects on Alzheimer's patients in four of the five efficacy variables examined in the trial.
 
- In view of the promising results of this trial, Noscira is preparing the next Phase IIb trial on Alzheimer's patients in order to progress with the clinical development of this novel compound.

 

03/11/2009
FDA AND EUROPEAN COMMISSION GRANT NOSCIRA (GRUPO ZELTIA) ORPHAN DRUG STATUS FOR NYPTA® TO TREAT A TYPE OF DEMENTIA  More Information
• Health authorities in both the European Union and the US have granted Noscira, a Grupo Zeltia subsidiary, orphan drug status for Nypta® (NP-12) to treat Progressive Supranuclear Palsy (PSP), a type of dementia.

• Nypta® is one of the compounds with the greatest potential for treating neurodegenerative disorders due to the way it modifies disease progression. It is also undergoing Phase II clinical trials on Alzheimer's disease.
22/05/2009
CONVOCATORIA JUNTA GENERAL DE ACCIONISTAS 2009  More Information
10/03/2009
Noscira presents new advances in the research on Alzheimer's disease   More Information
26/01/2009
Noscira launches a capital increase of 25 million euros led by Renta 4  More Information
17/10/2008
El Grupo Zeltia consolida el liderazgo de sus tres principales compañías  More Information
10/09/2008
Neuropharma embarks on a new era with a new name: “NOSCIRA”   More Information
31/07/2008
Neuropharma reports last results on its research in Alzheimer’s disease, at the International Conference of Alzheimer’s Disease held in Chicago on July 26-31  More Information
10/04/2007
Neuropharma starts clinical development with NP 61, its second compound for the treatment of Alzheimer’s disease  More Information
19/03/2007
Neuropharma presents advances in the development of NP-61 at the Alzheimer’s and Parkinson’s Diseases International Conference  More Information
1 2 Next

Noscira News
Interest Information

Postal Adress:
Noscira, S.A.
Avda. de la Industria, 52
Tres Cantos 28760 - Madrid (Spain)

E-mail adresses:
Administration and General services:
noscira@noscira.com
Research:
info_di@noscira.com

Phone Numbers:
Tel. +34 91 806 11 30
Fax. +34 91 803 46 60
© 2008 Noscira S.A. tel. 91 806 11 30 noscira@noscira.com